Caricamento...
The choice of first-line Chronic Myelogenous Leukemia treatment
Imatinib has represented a revolution in the treatment of chronic myeloid leukemia (CML), inducing an overall survival never seen with previous therapies. However, with the commonly used dosage of 400 mg, one third of the treated patients does not reach the criteria associated with an optimal outcom...
Salvato in:
| Pubblicato in: | Ann Hematol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Berlin Heidelberg
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4375302/ https://ncbi.nlm.nih.gov/pubmed/25814078 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-015-2321-3 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|